Vizimpro 45 mg Tablet
Prescription Required
Brand Name:
Vizimpro
Molecule:
DacomitinibStrength:
45 mg
Quantity:
30 Tablets
Form:
Tablet
Packaging Type:
Bottle
Manufacturer/Marketed By:
PfizerCountry of Origin:
U.S
Enquiry Form
Similar Products:
| Product | Manufacturer / Marketed By | Price |
|---|---|---|
| Daconib Dacomitinib 45 mg Tablet | Everest Pharma | Ask for Price |
Description
Vizimpro (dacomitinib) is a once‑daily, first‑generation, irreversible EGFR tyrosine kinase inhibitor used for adults with metastatic non‑small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations. It’s taken orally with or without food
Benefits
-
In the pivotal ARCHER 1050 trial, Vizimpro demonstrated a median progression‑free survival (PFS) of 14.7 months, compared to 9.2 months with gefitinib (hazard ratio 0.59; p < 0.0001)
-
Real‑world data suggest even longer median PFS (~16.7 months), with an overall response rate of 84.3%
-
Trend toward improved overall survival versus first-generation EGFR TKIs
Indications and Usage
-
First-line treatment of metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R substitution, confirmed via FDA‑approved tests
-
The safety and efficacy of this medication have not been established in children.
How it Works
Dacomitinib irreversibly binds and inhibits mutated EGFR family proteins, blocking downstream signaling that drives cancer proliferation. As a second-generation EGFR TKI, it also targets HER2, offering broader kinase suppression
Dosage & Administration
-
Recommended dose: 45 mg orally once daily (with or without food) until disease progression or unacceptable toxicity.
-
Take at the same time each day. If vomiting occurs shortly after dosing, skip that day’s dose and continue with the next day’s dose. Do not double up.
Side Effects
Common (≥20% incidence):
-
Diarrhea, rash, paronychia (nail infections), stomatitis, decreased appetite, dry skin, weight loss, alopecia, cough, pruritus
Serious Adverse Events:
-
Interstitial lung disease (ILD)/pneumonitis (incidence: 0.5%; fatality: 0.3%): monitor for worsening respiratory symptoms
-
Severe diarrhea and risk of dehydration: prompt treatment with fluids and agents such as loperamide.
-
Dermatologic reactions: dry skin, acneiform rash, and peeling. Prophylactic moisturizers and sun protection are advised.
-
Other symptoms include mouth sores, nail issues, eye irritation, and weight loss.
Warning and Precaution
-
ILD/pneumonitis: permanently discontinue on confirmed diagnosis; monitor for dyspnea, cough, fever.
-
Diarrhea may be severe; manage aggressively with hydration and anti-diuretics.
-
Skin toxicity: moisturize, use sunscreen, avoid tanning beds. Protective clothing is advised. Visit
-
Reproductive risks: contraindicated in pregnancy — effective contraception required during treatment and for 17 days after the last dose. Not to be used while breastfeeding.
-
Drug interactions: Acid-reducing agents should be spaced at least 6 hours apart from Vizimpro.
Clinical Trial & Approvals
-
ARCHER 1050 (NCT01774721): randomized trial comparing Vizimpro vs gefitinib; significant PFS benefit (14.7 vs 9.2 months; HR 0.59)
-
FDA Approval: September 2018 for first-line treatment of EGFR-mutated metastatic NSCLC
-
Real-world studies have validated efficacy with PFS around 16.7 months and high response rates.
FAQ
Who is Vizimpro intended for?
Can I take Vizimpro with food?
What should I do if I miss a dose?
How is diarrhea managed while on Vizimpro?
Related Products
Lucirux Ruxolitinib 5 mg Tablet
Molecule: Ruxolitinib
Manufacturer: Lucius Pharma
Ask for Price
Enquiry Form
Related Posts:
No matching posts found.
Reviews
Clear filtersThere are no reviews yet.